Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immuron Limited (IMRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0699-0.0801 (-3.73%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Previous Close2.1500
Open2.1000
Bid1.9400 x 1000
Ask2.1500 x 1000
Day's Range2.0000 - 2.2000
52 Week Range2.0000 - 4.4780
Volume9,919
Avg. Volume4,352
Market Cap12.7M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.5600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immuron Limited
    Daily – Vickers Top Insider Picks for 06/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Immuron CEO, Steven Lydeamore, to host an investor webinar

    MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited. Wednesday, 7 September 2022 at 9.00am Australian Eastern Standard Time (AEST).Register in advance for this webinar:https://us02web.zoom.us/webinar/register/W

  • Benzinga

    Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape

    Immuron Limited (NASDAQ: IMRN) has deprioritized SARS-CoV-2 research to focus on the clinical development of more advanced-stage therapeutic drug candidates. Immuron enters FY23 with a newly appointed CEO completing an assessment of the entire product portfolio, target markets, competitive advantage, and key growth drivers. Related: Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19. Considering research findings, the rapid evolution of the virus and changing treatment la

  • GlobeNewswire

    Immuron Update on IMM-124E SARS-CoV-2 Research

    MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates. Immuron enters FY23 with a newly appointed CEO who is completing an assessment of the entire pr

Advertisement
Advertisement